Search Results - "Dumagay, Teresita"

PB2247: BURDEN OF SYMPTOMS AND SYMPTOM EXPERIENCE OF FILIPINO MYELOPROLIFERATIVE NEOPLASM PATIENTS: A QUALITATIVE PHENOMENOLOGICAL STUDY by Mesina, Flordeluna, Dumagay, Teresita

Get full text

The Burden of symptoms and Quality of life of Filipino patients with Myeloproliferative neoplasm: A Multicenter Cross-sectional survey by Mesina, Flordeluna Z, Dumagay, Teresita E, Alejandria, Marissa M

“…Myeloproliferative neoplasms (MPN) are hematologic malignancies characterized by cellular proliferation of one or more hematopoietic cell lines. Management has…”
Get full text

Burden of Symptoms and Symptom Experience of Filipino Patients with Myeloproliferative Neoplasm: A Qualitative Phenomenological Approach by Mesina, Flordeluna Z., Dumagay, Teresita E., Alejandria, Marissa M., Castillo-Carandang, Nina T.

Get full text

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition by Röth, Alexander, He, Guangsheng, Tong, Hongyan, Lin, Zenghua, Wang, Xiaoqin, Chai‐Adisaksopha, Chatree, Lee, Je‐Hwan, Brodsky, Andres, Hantaweepant, Chattree, Dumagay, Teresita E., Demichelis‐Gómez, Roberta, Rojnuckarin, Ponlapat, Sun, Jing, Höglund, Martin, Jang, Jun Ho, Gaya, Anna, Silva, Fernando, Obara, Naoshi, Kelly, Richard J., Beveridge, Leigh, Buatois, Simon, Chebon, Sammy, Gentile, Brittany, Lundberg, Pontus, Sreckovic, Sasha, Nishimura, Jun‐ichi, Risitano, Antonio, Han, Bing

“…Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low‐volume self‐administration every 4 weeks…”
Get full text

Expert consensus on the management of chronic lymphocytic leukaemia in Asia by Tse, Eric, Kwong, Yok Lam, Goh, Yeow Tee, Bee, Ping Chong, Ng, Soo Chin, Tan, Daryl, Caguioa, Priscilla, Nghia, Huynh, Dumagay, Teresita, Norasetthada, Lalita, Chuncharunee, Suporn, Radhakrishnan, Vivek, Bagal, Bhausaheb, Atmakusuma, Tubagus Djumhana, Mulansari, Nadia Ayu

“…In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent…”
Get full text

The hematologic profile of Filipino HIV-infected individuals and its association with CD4 counts by Vaswani, Preeti Prerna M, Senga-Tang, Issa Rufina, Catapia, Jean Rachel M, Abad, Cybele Lara R, Dumagay, Teresita E

“…Hematologic abnormalities are common in HIV and involve all blood cell lineages. A study on cytopenias, as correlated with disease progression, can be valuable…”
Get full text

Longitudinally extensive transverse myelitis as a rare paraneoplastic presentation in chronic myelogenous leukemia by Lucero, Josephine Anne, Balane, Janika Adrienne, Roberto, Katrina, Dumagay, Teresita

“…Paraneoplastic syndromes are clinical syndromes involving nonmetastatic systemic effects that accompany malignant disease. It is estimated that up to 8% of…”
Get full text

Trisomy 5 as the sole chromosomal anomaly in acute lymphoblastic leukaemia by Vaswani, Preeti Prerna M, Dumagay, Teresita E

“…Trisomy 5 as the sole cytogenetic aberration in acute lymphoblastic leukaemia (ALL) is exceedingly rare. As such, its prognostic and therapeutic relevance…”
Get full text

S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS by Röth, Alexander, He, Guangsheng, Brodsky, Andres, Chai‐Adisaksopha, Chatree Chatree, Dumagay, Teresita, Demichelis, Roberta, Höglund, Martin, Kelly, Richard, Lee, Je‐Hwan, Nishimura, Jun‐Ichi, Obara, Naoshi, Risitano, Antonio Maria, Gaya, Anna, Appius, Anita, Gentile, Brittany, Negricea, Raluca, Zhang, Zilu, Buatois, Simon, Han, Bing

Get full text

Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients with COVID-19: The Co-CLARITY Trial by Gauiran, Deonne Thaddeus V., Dumagay, Teresita E., Ang, Mark Angelo C., Dungog, Cecile C., Climacosa, Fresthel Monica M., Maganito, Sandy Chiong, Alfonso, Rachelle N., Quero, Anne Kristine H., Lucero, Josephine Anne C., Cortez, Carlo Francisco N., Evasan, Agnes Lorrainne M., King, Ruby Anne Natividad, Heralde, Francisco M., Bonifacio, Lynn B., Castillo, German J., Escasa, Ivy Mae S., Santos, Maria Clariza M., Malundo, Anna Flor G., Mondragon, Alric V., Salamat, Saubel Ezreal A., Veloso, Januario D., Carnate, Jose M., Tagayuna, Pedrito Y., Lim, Jodor A., Alejandria, Marissa M., Mirasol, Ma. Angelina L.

Get full text

The Use of Convalescent Plasma Therapy on COVID-19 Filipino Patients: A Tertiary Center Experience by Velasco, Manuel Reyes, Relos, Jesus Alvarez, Torres, Rosalio P., Pelobello-De Leon, Maria Regina Valencia, Dumagay, Teresita, Lafavilla, Jimmy Reyes, Ongkingco, June Marie, Velasco, Theresa Marie S., Lim, Mark Allan

Get full text

MDS-113 Pegcetacoplan Rapidly Stabilizes Complement-Inhibitor Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria Experiencing Hemolysis With Acute Hemoglobin Decreases: A Post Hoc Analysis from the Phase 3 PRINCE Trial by Desai, Dharmik, Wong, Raymond, Al-Adhami, Mohammed, Savage, Jessica, Horneff, Regina, Yeh, Michael, Dumagay, Teresita, Gomez-Almaguer, David

Get full text

Poster: MDS-113 Pegcetacoplan Rapidly Stabilizes Complement-Inhibitor Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria Experiencing Hemolysis With Acute Hemoglobin Decreases: A Post Hoc Analysis from the Phase 3 PRINCE Trial by Desai, Dharmik, Wong, Raymond, Al-Adhami, Mohammed, Savage, Jessica, Horneff, Regina, Yeh, Michael, Dumagay, Teresita, Gomez-Almaguer, David

Get full text

Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study by Wong, Raymond S, Navarro, Juan Ramon, Comia, Narcisa Sonia, Goh, Yeow Tee, Idrobo, Henry, Kongkabpan, Daolada, Gomez-Almaguer, David, Al-Adhami, Mohammed, Ajayi, Temitayo, Alvarenga, Paulo, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Dumagay, Teresita

“…Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and life-threatening disease characterized by hemolysis and thrombosis. Many patients with PNH…”
Get full text

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria by Wong, Raymond Siu Ming, Navarro-Cabrera, Juan Ramon, Comia, Narcisa Sonia, Goh, Yeow Tee, Idrobo, Henry, Kongkabpan, Daolada, Gómez-Almaguer, David, Al-Adhami, Mohammed, Ajayi, Temitayo, Alvarenga, Paulo, Savage, Jessica, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Dumagay, Teresita

“…•Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control.•Pegcetacoplan’s…”
Get full text